Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Growth Hormone Deficiency Reversal Trial
2022-502008-62-00Phase 3Completed
- Sponsor
- University College London
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by University College London. Primary endpoint: Final Height in Standard Deviation Score (FH SDS). Started Mar 2023; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on 2022-502008-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502008-62-00.